Sovremennye podkhody k lecheniyu dislipidemiy: differentsirovannaya gipolipidemicheskaya terapiya
- Authors: Lupanov V.P1
-
Affiliations:
- Issue: No 17 (2012)
- Pages: 41-46
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279961
- ID: 279961
Cite item
Open Access
Access granted
Abstract
The article considers the issues of differential treatment of various dyslipidemias with the purpose of prevention of atherosclerosis and its complications. The main classes of lipid-lowering drugs and characteristics of their use depending on the cardiovascular risk and type of dyslipidemia are presented.
Full Text
References
- Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769-818.
- Mills E.J., Rachlis B., Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.
- Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. ВНОК, 2011 //Рациональная Фармакотерапия в кардиологии 2011. № 7 (5) Прил. С. 2-72.
- Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009;338:b2376.
- Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S): Scandinavian Simvastatin Survival study Group. Lancet 1994;344:1383-89.
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
- Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010;24:19-28.
- Conroy R., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
- Tyroler H.A. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984;54:14-109.
- Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
- Keech A., Simes R.J., Barter P., et al. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
- Bruckert E., Labreuche J., Amarenco P. Metaanalysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353-61.
- Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30.
- Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel blinded endpoit analysis. Lancet 2007;369:1090-98.
- McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-37.
- Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
- Davidson M.H., Stein E.A., Bays H.E., et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding rescription omega-3-fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67.
- Аронов Д.М., Лупанов В.П. Атеросклероз и коронарная болезнь сердца. Изд. 2-е, переработ. М., 2009. 248 с.
- Кардиоваскулярная профилактика. Национальные рекомендации. Разработаны Комитетом экспертов ВНОК, Москва 2011 // Кардиоваск. терапия и профилактика 2011. № 10 (6). Прил. 2. С. 1-64.
- Кухарчук В.В. Комментарий к последней версии рекомендаций "Руководство по лечению дислипидемий", подготовлен ного Рабочей группой по лечению дислипидемий ЕКО и ЕОА при участии Европейской ассоциации профилактики сердечно-сосудистых заболеваний // Атеросклероз и дислипидемии 2011. № 4. C. 70-2.
- Barter P.J., Caulfield M., Eriksson M., et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
Supplementary files
